DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Bid/Ask 12:38:55 12/06/2024 am IST | ||
| 313.6 EUR | +0.10% |
|
| Current month | +1.79% | ||
| 1 month | +2.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 12/24/12 | 313.6 | +0.10% |
| 10/24/10 | 313.3 | +0.38% |
| 07/24/07 | 312.2 | +0.86% |
| 06/24/06 | 309.5 | -0.10% |
| 05/24/05 | 309.8 | +0.42% |
Delayed Quote Börse Stuttgart
Last update June 12, 2024 at 12:38 am IST
More quotesStatic data
| Product type | Certificati Discount |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG1BT0 |
| ISIN | DE000MG1BT02 |
| Date issued | 02/04/2024 |
| Maturity | 21/03/2025 (283 Days) |
| Parity | 1 : 1 |
| Emission price | 300.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 314.4 € |
|---|---|
| Lowest since issue | 295.7 € |
| Spread | 0.32 € |
| Spread % | 0.10% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483.3
USD
Average target price
463.4
USD
Spread / Average Target
-4.11%
- Stock Market
- Certificates
- Certificat
